{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '79', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.1.2', 'Dose Modification and Toxicity Management of Infusion Reactions Related', 'to Pembrolizumab', 'Pembrolizumab may cause severe or life-threatening infusion reactions, including severe', 'hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after', 'drug infusion and generally resolve completely within 24 hours of completion of infusion.', 'Dose modification and toxicity management guidelines for pembrolizumab-associated', 'infusion reactions are provided in Table 4.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '80', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 4', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment Guidelines', 'NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grade 1', 'Increase monitoring of vital signs as medically indicated until the participant is', 'None', 'Mild reaction; infusion', 'deemed medically stable in the opinion of the investigator.', 'interruption not indicated;', 'intervention not indicated', 'Grade 2', 'Stop Infusion.', 'Participant may be premedicated 1.5 h', 'Requires therapy or infusion', 'Additional appropriate medical therapy may include but is not limited to the', '( 30 minutes) before infusion of', 'interruption but responds', 'following:', 'pembrolizumab with:', 'promptly to symptomatic', '-', 'IV fluids', '-', 'Diphenhydramine, 50 mg PO (or', 'treatment (eg, antihistamines,', '-', 'Antihistamines', 'equivalent dose of antihistamine).', 'NSAIDs, narcotics, IV fluids);', '-', 'NSAIDs', '-', 'Acetaminophen, 500-1000 mg PO (or', 'prophylactic medications', '-', 'Acetaminophen', 'equivalent dose of analgesic).', 'indicated for <24 h', '-', 'Narcotics', 'Increase monitoring of vital signs as medically indicated until the participant is', 'deemed medically stable in the opinion of the investigator.', 'If symptoms resolve within 1 hour of stopping drug infusion, the infusion may', 'be restarted at 50% of the original infusion rate (eg, from 100 mL/h to', '50 mL/h). Otherwise, dosing will be held until symptoms resolve and the', 'participant should be premedicated for the next scheduled dose.', 'Participants who develop Grade 2 toxicity despite adequate premedication', 'should be permanently discontinued from further pembrolizumab', 'treatment.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '81', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grades 3 or 4', 'Stop Infusion.', 'No subsequent dosing', 'Grade 3:', 'Additional appropriate medical therapy may include but is not limited to:', 'Prolonged (ie, not rapidly', '-', 'Epinephrine**', 'responsive to symptomatic', '-', 'IV fluids', 'medication and/or brief', '-', 'Antihistamines', 'interruption of infusion);', '-', 'NSAIDs', 'recurrence of symptoms', '-', 'Acetaminophen', 'following initial improvement;', '-', 'Narcotics', 'hospitalization indicated for', '-', 'Oxygen', 'other clinical sequelae (eg, renal', '-', 'Pressors', 'impairment, pulmonary', '-', 'Corticosteroids', 'infiltrates)', 'Increase monitoring of vital signs as medically indicated until the participant is', 'Grade 4:', 'deemed medically stable in the opinion of the investigator.', 'Life-threatening; pressor or', 'Hospitalization may be indicated.', 'ventilatory support indicated', '**In cases of anaphylaxis, epinephrine should be used immediately.', 'Participant is permanently discontinued from further pembrolizumab', 'treatment.', 'Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; IV = intravenous; NCI = National Cancer Institute; NSAIDs = nonsteroidal anti-', 'inflammatory drugs; PO = by mouth.', 'Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration.', 'For further information, please refer to the CTCAE, version 4.0, at http://ctep.cancer.gov', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}